We have been busy here at HCSP preparing for the upcoming AASLD Conference in Boston. We will be providing extensive coverage of current therapies as well as new medications that are being developed to treat hepatitis B and hepatitis C. So stay tuned—the conference promises to yield a wealth of information about future treatment.
Newly posted items:
HCSP Fact Sheets: Boceprevir
—top line results of the pivotal phase III studies that have been conducted to date. This is the data that will be submitted to the Food and Drug Administration for marketing approval of the drugs
: including two very interesting stories: one about the discovery of a key enzyme that the hepatitis C virus needs to replicate, and a study about how the hepatitis C virus can infect and damage brain tissue
for supporting the Hepatitis & Liver Cancer Act
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org
**Questions and Comments: Questions and/or comments can be directed to email@example.com
**To receive the eblast in your email inbox simply send an e-mail to: firstname.lastname@example.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.